{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:25Z","timestamp":1777334425899,"version":"3.51.4"},"reference-count":67,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/BII-BTI\/30219\/2017 - POCI-01-0145-FEDER-030219"],"award-info":[{"award-number":["PTDC\/BII-BTI\/30219\/2017 - POCI-01-0145-FEDER-030219"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Persistent infections, usually associated with biofilm-producing bacteria, are challenging for both medical and scientific communities. The potential interest in drug repurposing for biofilm control is growing due to both disinvestment in antibiotic R&amp;D and reduced efficacy of the available panel of antibiotics. In the present study, the antibacterial and antibiofilm activities of four non-steroidal anti-inflammatory drugs (NSAIDs), piroxicam (PXC), diclofenac sodium (DCF), acetylsalicylic acid (ASA) and naproxen sodium (NPX) were evaluated against Escherichia coli and Staphylococcus aureus. The minimum inhibitory\/bactericidal concentrations (MICs and MBCs) and the dose\u2013response curves from exposure to the selected NSAIDs were determined. MICs were found for PXC (800 \u03bcg\/mL) and ASA (1750 \u03bcg\/mL) against E. coli, and for DCF (2000 \u03bcg\/mL) and ASA (2000 \u03bcg\/mL) against S. aureus. No MBCs were found (&gt;2000 \u03bcg\/mL). The potential of NSAIDs to eradicate preformed biofilms was characterized in terms of biofilm mass, metabolic activity and cell culturability. Additionally, the NSAIDs were tested in combination with kanamycin (KAN) and tetracycline (TET). ASA, DCF and PXC promoted significant reductions in metabolic activity and culturability. However, only PXC promoted biofilm mass removal. Additive interactions were obtained for most of the combinations between NSAIDs and KAN or TET. In general, NSAIDs appear to be a promising strategy to control biofilms as they demonstrated to be more effective than conventional antibiotics.<\/jats:p>","DOI":"10.3390\/antibiotics9090591","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T09:10:09Z","timestamp":1599729009000},"page":"591","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["NSAIDs as a Drug Repurposing Strategy for Biofilm Control"],"prefix":"10.3390","volume":"9","author":[{"given":"Cl\u00e1udia","family":"Le\u00e3o","sequence":"first","affiliation":[{"name":"LEPABE\u2014Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, s\/n, 4200-465 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-6805","authenticated-orcid":false,"given":"Anabela","family":"Borges","sequence":"additional","affiliation":[{"name":"LEPABE\u2014Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, s\/n, 4200-465 Porto, Portugal"},{"name":"DEQ\u2014Department of Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, s\/n, 4200-465 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3355-4398","authenticated-orcid":false,"given":"Manuel","family":"Sim\u00f5es","sequence":"additional","affiliation":[{"name":"LEPABE\u2014Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, s\/n, 4200-465 Porto, Portugal"},{"name":"DEQ\u2014Department of Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, s\/n, 4200-465 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2475067","DOI":"10.1155\/2016\/2475067","article-title":"Mechanisms of antimicrobial resistance in ESKAPE pathogens","volume":"2016","author":"Santajit","year":"2016","journal-title":"BioMed Res. Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.tibtech.2012.12.006","article-title":"Combination approaches to combat multidrug-resistant bacteria","volume":"31","author":"Worthington","year":"2013","journal-title":"Trends Biotechnol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/08927014.2012.706751","article-title":"The activity of ferulic and gallic acids in biofilm prevention and control of pathogenic bacteria","volume":"28","author":"Borges","year":"2012","journal-title":"Biofouling"},{"key":"ref_4","first-page":"32","article-title":"Biofilm prevention and control by dietary phytochemicals","volume":"Volume 1","year":"2013","journal-title":"Microbial Pathogens and Strategies for Combating Them: Science, Technology and Education"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.foodres.2016.06.006","article-title":"The current knowledge on the application of anti-biofilm enzymes in the food industry","volume":"86","author":"Meireles","year":"2016","journal-title":"Food Res. Int."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Patel, R. (2005). Biofilms and antimicrobial resistance. Clin. Orthop. Relat. Res., 41\u201347.","DOI":"10.1097\/01.blo.0000175714.68624.74"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/1874285801711010053","article-title":"Understanding the mechanism of bacterial biofilms resistance to antimicrobial agents","volume":"11","author":"Singh","year":"2017","journal-title":"Open Microbiol. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ijantimicag.2009.12.011","article-title":"Antibiotic resistance of bacterial biofilms","volume":"35","author":"Bjarnsholt","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.diagmicrobio.2014.03.002","article-title":"Evaluation of the best method to assess antibiotic potentiation by phytochemicals against Staphylococcus aureus","volume":"79","author":"Abreu","year":"2014","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"340","DOI":"10.20546\/ijcmas.2018.712.042","article-title":"Non-antibiotic compounds: The activity of the NSAID diclofenac on bacteria\u2014A review","volume":"7","author":"Silva","year":"2018","journal-title":"Int. J. Curr. Microbiol. Appl. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ibiod.2018.02.004","article-title":"Effect of plant-based catecholic molecules on the prevention and eradication of Escherichia coli biofilms: A structure activity relationship study","volume":"141","author":"Baptista","year":"2019","journal-title":"Int. Biodeterior. Biodegrad."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1586\/eri.13.12","article-title":"Clinical relevance of the ESKAPE pathogens","volume":"11","author":"Pendleton","year":"2013","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.molmed.2007.04.004","article-title":"New strategies for combating multidrug-resistant bacteria","volume":"13","author":"Wright","year":"2007","journal-title":"Trends Mol. Med."},{"key":"ref_14","first-page":"1403","article-title":"A review on antibiotic resistance: Alarm bells are ringing","volume":"9","author":"Hussain","year":"2017","journal-title":"Cureus"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fmicb.2010.00134","article-title":"A brief history of the antibiotic era: Lessons learned and challenges for the future","volume":"1","author":"Aminov","year":"2010","journal-title":"Front. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1155\/2005\/892058","article-title":"Where are all the new antibiotics? The new antibiotic paradox","volume":"16","author":"Conly","year":"2005","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Dheman, N., Mahoney, N., Cox, E.M., Farley, J.J., Amini, T., and Lanthier, M.L. (2020). An analysis of antibacterial drug development trends in the US, 1980\u20132019. Clin. Infect. Dis. Oxford Acad., Available online: https:\/\/academic.oup.com\/cid\/article\/doi\/10.1093\/cid\/ciaa859\/5862690.","DOI":"10.1093\/cid\/ciaa859"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"749","DOI":"10.5796\/electrochemistry.82.749","article-title":"Metal oxides and hydroxides as rechargeable materials for photocatalysts with oxidative energy storage abilities","volume":"82","author":"Takahashi","year":"2014","journal-title":"Electrochemistry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.drudis.2016.09.019","article-title":"Design of efficient computational workflows for in silico drug repurposing","volume":"22","author":"Vanhaelen","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.12793\/tcp.2019.27.2.59","article-title":"A review of computational drug repurposing","volume":"27","author":"Park","year":"2019","journal-title":"Transl. Clin. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1128\/AAC.00013-11","article-title":"Ecology and evolution as targets: The need for novel eco-evo drugs and strategies to fight antibiotic resistance","volume":"55","author":"Baquero","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","first-page":"344","article-title":"The antibiotic resistance crisis: Part 2: Management strategies and new agents","volume":"40","author":"Ventola","year":"2015","journal-title":"Pharm. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yan, Q. (2017). Translational bioinformatics methods for drug discovery and development. Transl. Bioinforma. Syst. Biol. Methods Pers. Med., 97\u2013110.","DOI":"10.1016\/B978-0-12-804328-8.00008-5"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm.4306","article-title":"The drug repurposing hub: A next-generation drug library and information resource","volume":"23","author":"Corsello","year":"2017","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2217\/fmb-2019-0122","article-title":"Update on drug-repurposing: Is it useful for tackling antimicrobial resistance?","volume":"14","author":"Kaul","year":"2019","journal-title":"Futur. Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e02268-16","DOI":"10.1128\/AAC.02268-16","article-title":"Antimicrobial effects of antipyretics","volume":"61","author":"Zimmermann","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jgar.2017.03.012","article-title":"Synergistic effect of non-steroidal anti-inflammatory drugs (NSAIDs) on antibacterial activity of cefuroxime and chloramphenicol against methicillin-resistant Staphylococcus aureus","volume":"10","author":"Chan","year":"2017","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_29","unstructured":"Abdul-Hussein, Z.R., and Zainab, R. (2019, January 04). Antibacterial Effect of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Antibacterial Effect of Non-Steroidal. Available online: https:\/\/www.iasj.net\/iasj?func=fulltext&aId=98815."},{"key":"ref_30","first-page":"7332","article-title":"Antimicrobial activity of non-steroidal anti-inflammatory drugs with respect to immunological response: Diclofenac sodium as a case study","volume":"8","author":"Umaru","year":"2009","journal-title":"Afr. J. Biotechnol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/j.1440-1746.2006.04194.x","article-title":"Non-steroidal anti-inflammatory drugs have bacteriostatic and bactericidal activity against Helicobacter pylori","volume":"21","author":"Shirin","year":"2006","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejmech.2019.01.046","article-title":"Repurposing ibuprofen to control Staphylococcus aureus biofilms","volume":"166","author":"Oliveira","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar4174","article-title":"Use of NSAIDs in treating patients with arthritis","volume":"15","author":"Crofford","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"81s","DOI":"10.18433\/J3T886","article-title":"Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): Cyclooxygenase (COX) inhibition and beyond","volume":"11","author":"Rao","year":"2008","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10096-009-0739-z","article-title":"The anti-inflammatory non-antibiotic helper compound diclofenac: An antibacterial drug target","volume":"28","author":"Mazumdar","year":"2009","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.chembiol.2014.02.009","article-title":"DNA replication is the target for the antibacterial effects of nonsteroidal anti-inflammatory drugs","volume":"21","author":"Yin","year":"2014","journal-title":"Chem. Biol."},{"key":"ref_37","first-page":"1","article-title":"Antibacterial, anti-biofilm activity of some non-steroidal anti-inflammatory drugs and n-acetyl cysteine against some biofilm producing uropathogens","volume":"3","author":"Mohsen","year":"2015","journal-title":"Am. J. Epidemiol. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1586\/14737175.6.11.1643","article-title":"Minimizing risks of NSAIDs: Cardiovascular, gastrointestinal and renal","volume":"6","author":"Davies","year":"2006","journal-title":"Expert Rev. Neurother."},{"key":"ref_39","unstructured":"eMC (2020, July 31). FELDENE\u2014Summary of Product Characteristics (SmPC). Available online: https:\/\/www.medicines.org.uk\/emc\/product\/2901\/smpc."},{"key":"ref_40","unstructured":"Garg, S.K. (2019, June 09). Development Characterization and Invivo Study of Floating Tablet of Aceclofenac. INFLIBNET, 2014. Available online: https:\/\/shodhganga.inflibnet.ac.in\/handle\/10603\/28939."},{"key":"ref_41","unstructured":"Medicines Agency (2019, June 09). Information for the Package Leaflet Regarding Lactose Used as an Excipient in Medicinal Products for Human Use. Available online: www.ema.europa.eu\/contact."},{"key":"ref_42","first-page":"3882","article-title":"Eradication of biofilms formed by bacteria isolated from diabetic foot infections by potential antibiofilm agents alone and in combination with ciprofloxacin","volume":"8","author":"Abbas","year":"2014","journal-title":"Afr. J. Microbiol. Res."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Laudy, A.E., Mr\u00f3wka, A., Krajewska, J., and Tyski, S. (2016). The influence of efflux pump inhibitors on the activity of non-antibiotic NSAIDS against gram-negative rods. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0147131"},{"key":"ref_44","first-page":"44","article-title":"M100-S25 Performance Standards for Antimicrobial Susceptibility Testing","volume":"35","author":"Patel","year":"2015","journal-title":"Clin. Lab. Stan. Inst."},{"key":"ref_45","unstructured":"Wootton, M. (2019, June 12). BSAC Methods for Antimicrobial Susceptibility Testing. Available online: http:\/\/bsac.org.uk\/wp-content\/uploads\/2012\/02\/Version-12-Apr-2013_final.pdf."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/pharmaceutics4030413","article-title":"Diclofenac salts, VIII. Effect of the counterions on the permeation through porcine membrane from aqueous saturated solutions","volume":"4","author":"Fini","year":"2012","journal-title":"Pharmaceutics"},{"key":"ref_47","unstructured":"Tocris Bioscience (2020, August 18). Diclofenac Sodium Salt Supplier CAS 15307-79-6. Available online: https:\/\/www.tocris.com\/products\/diclofenac-sodium-salt_4454."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1128\/AAC.45.4.999-1007.2001","article-title":"Riddle of biofilm resistance","volume":"45","author":"Lewis","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Malheiro, J.F., Maillard, J.Y., Borges, F., and Sim\u00f5es, M. (2019). Biocide potentiation using cinnamic phytochemicals and derivatives. Molecules, 24.","DOI":"10.3390\/molecules24213918"},{"key":"ref_50","first-page":"79","article-title":"Inhibition of virulence factors of Pseudomonas aeruginosa by diclofenac sodium","volume":"74","author":"Abbas","year":"2016","journal-title":"Roum. Arch. Microbiol. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.micpath.2014.07.008","article-title":"Aspirin is an efficient inhibitor of quorum sensing, virulence and toxins in Pseudomonas aeruginosa","volume":"74","author":"Shaaban","year":"2014","journal-title":"Microb. Pathog."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.1128\/IAI.67.10.5427-5433.1999","article-title":"The Intercellular Adhesion (ica) Locus Is Present in Staphylococcus aureus and Is Required for Biofilm Formation","volume":"67","author":"Cramton","year":"1999","journal-title":"Infect. Immun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"694","DOI":"10.5897\/AJMR2016.8013","article-title":"Effect of non-steroidal anti-inflammatory drugs and dexamethazone on the biofilm formation and expression of some adhesion-related genes of Candida albicans and Staphylococcus aureus","volume":"10","author":"Sherein","year":"2016","journal-title":"Afr. J. Microbiol. Res."},{"key":"ref_54","first-page":"66","article-title":"Antibacterial activity of some non-steroidal anti-inflammatory drugs against bacteria causing urinary tract infection","volume":"5","author":"Ahmed","year":"2017","journal-title":"Am. J. Infect. Dis. Microbiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/1573406411006030174","article-title":"Antimicrobial activity of phenolics and glucosinolate hydrolysis products and their synergy with streptomycin against pathogenic bacteria","volume":"6","author":"Saavedra","year":"2010","journal-title":"Med. Chem."},{"key":"ref_56","first-page":"795435","article-title":"Antibacterial effects and mode of action of selected essential oils components against Escherichia coli and Staphylococcus aureus","volume":"2015","author":"Borges","year":"2015","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ibiod.2013.01.015","article-title":"The action of selected isothiocyanates on bacterial biofilm prevention and control","volume":"86","author":"Borges","year":"2014","journal-title":"Int. Biodeterior. Biodegrad."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0167-7012(00)00122-6","article-title":"A modified microtiter-plate test for quantification of staphylococcal biofilm formation","volume":"40","year":"2000","journal-title":"J. Microbiol. Methods"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/jam.13490","article-title":"Prevention, removal and inactivation of Escherichia coli and Staphylococcus aureus biofilms using selected monoterpenes of essential oils","volume":"123","author":"Borges","year":"2017","journal-title":"J. Appl. Microbiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ibiod.2013.06.011","article-title":"The effects of ferulic and salicylic acids on Bacillus cereus and Pseudomonas fluorescens single- and dual-species biofilms","volume":"86","author":"Lemos","year":"2014","journal-title":"Int. Biodeterior. Biodegrad."},{"key":"ref_61","unstructured":"Salutas Pharma GmbH (2020, July 31). Information Leaflet: Diclofenac Sodium; INFARMED, 2014. Available online: https:\/\/extranet.infarmed.pt\/INFOMED-fo\/pesquisa-avancada.xhtml."},{"key":"ref_62","unstructured":"Bayer Bitterfeld GmbH (2020, July 31). Information Leaflet: Acetylsalicylic Acid; INFARMED, 2008. Available online: https:\/\/extranet.infarmed.pt\/INFOMED-fo\/pesquisa-avancada.xhtml."},{"key":"ref_63","unstructured":"Laboratorios CINFA (2020, July 31). Information Leaflet: Piroxicam. INFARMED, 2008. Available online: http:\/\/app7.infarmed.pt\/infomed\/download_ficheiro.php?med_id=37208&tipo_doc=fi."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1111\/pme.12288","article-title":"Topical NSAID formulations","volume":"14","author":"McPherson","year":"2013","journal-title":"Pain Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0011-393X(05)80654-X","article-title":"Short-term topical piroxicam has no anti-inflammatory or antinociceptive effects after burn injury","volume":"53","author":"Dahl","year":"1993","journal-title":"Curr. Ther. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/11311170-000000000-00000","article-title":"Topical treatment of actinic keratoses with piroxicam 1% gel","volume":"11","author":"Campione","year":"2010","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF00609198","article-title":"Transcutaneous absorption of naproxen gel","volume":"36","author":"Eenhoorn","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/9\/591\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:08:37Z","timestamp":1760177317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/9\/591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":67,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["antibiotics9090591"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics9090591","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]}}}